Diligence memo · auto-generated · as of July 2, 2026
Avenacy Inc.
Avenacy Inc. looks fair against its niche peers and is quiet on financing cadence.
Businessfiled
Avenacy Inc. operates in Pharmaceuticals, based in SCHAUMBURG.
No verified homepage on file yet — operating evidence is limited to the public record.
Capital & rounds (filed)filed
Avenacy Inc. has raised $26M in disclosed capital across 1 recorded round, aggregated from public filings. Its latest round is modeled as Series B (a $15M–$40M round).
Largest single filing: $26M on 2024-11-15.
Most recent recorded round closed around 2024-11-15.
Valuation (modeled)modeled
Provath models Avenacy Inc. at approximately $157M (range $55M–$262M). This is an algorithmic estimate from round sizes and same-niche peers — not a quoted or reported figure.
Read: Fair. Modeled value is 1.21× the median modeled value of Series B Pharmaceuticals companies in 2022–2024 (51 peers) — value vs value, same stage and era. Within the normal band (121% of peer median) for its niche.
Financing rhythm & timingmixed
Last raise 20 mo ago; this sector typically re-raises about every 13 months.
Slightly overdue versus sector cadence.
Comparablesmixed
Capital scale ranks ahead of 70% of Pharmaceuticals peers (1613 compared).
Modeled value ranks above 65% of those peers.
Closest niche peers: MedAvail Holdings, Inc., Revalesio Corp, Kinaset Therapeutics, Inc., Venatorx Pharmaceuticals, Inc., Cxl Ophthalmics, Inc..
Peoplefiled
5 named people on file across officers, directors and signatories.
Risks & flagsmixed
No clearly named CEO/founder/principal in the surfaced records — key-person evidence is thin.